AstraZeneca (AZN.L), opens new tab said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was safe and tolerable in an early-stage trial ...
Previous research from the same team showed that older participants with a mean age of 54 who took IPE supplements ... The ...
AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker's closely watched weight loss pill, AZD5004 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback